Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Journal of Clinical Medicine|June 20, 2019
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM TrialPeter C Taylor, Yvonne C Lee, Roy Fleischmann, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2026
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritisJinqi Liu, Yicong Li, Kai Fu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug TreatmentRoy Fleischmann, Michael Schiff, Désirée van der Heijde, et al.
Rheumatology and Therapy|March 3, 2023
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
Annals of Internal Medicine|August 19, 2009
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trialRaphaela Goldbach-Mansky, Mildred Wilson, Roy Fleischmann, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Journal of Clinical Medicine|June 20, 2019
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM TrialPeter C Taylor, Yvonne C Lee, Roy Fleischmann, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2026
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritisJinqi Liu, Yicong Li, Kai Fu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug TreatmentRoy Fleischmann, Michael Schiff, Désirée van der Heijde, et al.
Rheumatology and Therapy|March 3, 2023
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
Annals of Internal Medicine|August 19, 2009
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trialRaphaela Goldbach-Mansky, Mildred Wilson, Roy Fleischmann, et al.
Pageof 19